Literature DB >> 11705136

Current perspective in the diagnosis and treatment of adrenocortical carcinoma.

D E Schteingart1.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11705136     DOI： 10.1023/a:1011576702293

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN： 1389-9155            Impact factor:   6.514


× No keyword cloud information.
  53 in total

1.  Comment--Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?

Authors:  L Barzon; F Fallo; N Sonino; O Daniele; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  1999-04       Impact factor: 5.958

2.  The in vitro metabolism of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p'-DDD) by dog adrenal mitochondria and metabolite covalent binding to mitochondrial macromolecules: a possible mechanism for the adrenocorticolytic effect.

Authors:  F Martz; J A Straw
Journal:  Drug Metab Dispos       Date:  1977 Sep-Oct       Impact factor: 3.922

3.  Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer.

Authors:  A A Kasperlik-Załuska; B Migdalska; A Makowska
Journal:  Cancer       Date:  1994-03-01       Impact factor: 6.860

4.  Magnetic resonance imaging of adrenal cortical carcinoma.

Authors:  S M Smith; S K Patel; D A Turner; T A Matalon
Journal:  Urol Radiol       Date:  1989

5.  Amino-glutethimide and metastatic adrenal cancer. Maintained reversal (six months) of Cushing's syndrome.

Authors:  D E Schteingart; R Cash; J W Conn
Journal:  JAMA       Date:  1966-11-28       Impact factor: 56.272

6.  Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect.

Authors:  R V La Rocca; C A Stein; R Danesi; C A Jamis-Dow; G H Weiss; C E Myers
Journal:  J Clin Endocrinol Metab       Date:  1990-08       Impact factor: 5.958

7.  5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma.

Authors:  M Schlumberger; L Brugieres; C Gicquel; J P Travagli; J P Droz; C Parmentier
Journal:  Cancer       Date:  1991-06-15       Impact factor: 6.860

8.  Aldosterone-producing adrenocortical carcinoma. Preoperative recognition and course in three cases.

Authors:  E Arteaga; E G Biglieri; C E Kater; J M Lopez; M Schambelan
Journal:  Ann Intern Med       Date:  1984-09       Impact factor: 25.391

9.  p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies.

Authors:  M Reincke; M Karl; W H Travis; G Mastorakos; B Allolio; H M Linehan; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

10.  Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.

Authors:  J P Luton; S Cerdas; L Billaud; G Thomas; B Guilhaume; X Bertagna; M H Laudat; A Louvel; Y Chapuis; P Blondeau
Journal:  N Engl J Med       Date:  1990-04-26       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.